Bionime (4737.TW) Stock Price
Bionime Price
Revenue has compounded at 12.6% per year over the past 19 years to 1.84 B TWD. Earnings per share have declined at 8.4% per year over the last 16 years. Bionime's net margin stands at -9.8%, down from 4.7% several years earlier. Bionime currently offers a dividend yield of about 3.19%.
Bionime stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Bionime business model & stock analysis
Frequently asked questions about Bionime
The business model of Bionime Corp is focused on developing and manufacturing advanced medical devices and solutions for diabetes management. They specialize in creating innovative blood glucose monitoring systems, including blood glucose meters, test strips, and other related products. Bionime Corp aims to provide accurate and reliable diabetes management tools to help individuals effectively monitor their blood sugar levels and make informed decisions about their health. With their commitment to technological advancements and quality products, Bionime Corp strives to improve the lives of people living with diabetes worldwide.
Bionime Corp primarily operates in the healthcare and medical equipment industries.
Bionime Corp faces competition from prominent players in the market such as Abbott Laboratories, Roche Holding AG, and Johnson & Johnson. These companies are also engaged in the development and manufacturing of medical devices, including glucose monitoring systems. However, Bionime Corp stands out with its innovative products and solutions, such as their blood glucose monitoring systems and diabetes management applications. With its focus on providing accurate and user-friendly products, Bionime Corp has carved a niche for itself in the market, distinguishing itself from its competitors through its commitment to high-quality healthcare solutions.
Bionime Corp is a renowned global medical technology company specializing in the development, manufacturing, and marketing of innovative healthcare products. Established in 2003, Bionime has made significant strides in the field of diabetes management. With a commitment to improving the lives of individuals living with diabetes, Bionime focuses on developing advanced blood glucose monitoring systems and related solutions. The company's expertise lies in creating user-friendly, accurate, and reliable products that empower patients to effectively manage their condition. With a strong emphasis on research and development, Bionime has emerged as a trusted brand in the healthcare industry, continuously striving for technological advancements and breakthroughs in diabetes care.
Significant milestones achieved by Bionime Corp include the development of innovative medical devices and solutions, establishing a strong global presence, and receiving numerous certifications and awards. The company has successfully launched advanced products such as blood glucose monitoring systems and continuous glucose monitoring systems, which have improved the lives of individuals managing diabetes. Bionime Corp has expanded its market reach by establishing partnerships and distribution networks in various countries. Additionally, the company has earned recognition through certifications like ISO 13485 and FDA approvals for its quality management systems. These achievements highlight Bionime Corp's commitment to enhancing healthcare and creating impactful solutions for patients worldwide.
Bionime Corp is primarily present in several countries and regions. The company has a significant presence in Taiwan, where it is headquartered. Additionally, Bionime Corp operates in various Asian markets, including China, Hong Kong, Japan, and Southeast Asian countries. It has expanded its reach to the United States, Canada, and several European countries as well. Bionime Corp's global presence allows it to serve a wide range of customers and cater to different markets' demands.
Bionime Corp represents a range of values and a corporate philosophy focused on innovation, quality, and customer satisfaction. The company is dedicated to developing advanced medical devices and solutions to meet the needs of healthcare professionals and patients. With a commitment to accuracy, reliability, and user-friendly products, Bionime Corp aims to enhance the management of diabetes and improve the overall quality of life for individuals living with the condition. By continuously investing in research and development, Bionime Corp strives to provide cutting-edge technology and personalized healthcare solutions to contribute to the well-being of its customers.
9 analysts currently rate the Bionime stock: 0 recommend buying, 3 holding and 6 selling.
Converted at the current exchange rate, the Bionime share trades at 1.55 EUR (56.50 TWD).
Bionime Corp is a global leader in diabetes management products and medical diagnostic devices. The company, headquartered in Taiwan with branches in Europe, North America, and Asia, focuses on developing innovative measuring devices and patient management systems to improve the health of diabetes patients.
The revenue cannot currently be calculated for Bionime.
The profit cannot currently be calculated for Bionime.
The P/E ratio cannot be calculated for Bionime at the moment.
The P/S cannot be calculated for Bionime currently.
The Eulerpool Quality Score for Bionime is 1/10.
The ISIN of Bionime is TW0004737002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Bionime is 4737.TW. The ticker symbol is used to trade Bionime shares on the stock exchange.
Bionime stock
Bionime Peer Group
Bionime FIGI
All fundamentals and in-depth analysis of Bionime
Our stock analysis for Bionime stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bionime. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.